Bipolar Disorder Clinical Trial
Official title:
Anti-Estrogens - A Potential Treatment for Bipolar Affective Disorder in Women?
Verified date | October 2008 |
Source | The Alfred |
Contact | n/a |
Is FDA regulated | No |
Health authority | Australia: Human Research Ethics Committee |
Study type | Interventional |
OBJECTIVE:
To test the use of two adjunctive hormonal agents in a 28 day three-arm, double-blind,
placebo-controlled study in the treatment of acute mania/hypomania.
HYPOTHESIS:
That women receiving adjunctive Tamoxifen or Progesterone will demonstrate a more rapid and
more substantial decrease in manic symptoms over the course of the study than women
receiving adjunctive placebo.
STUDY POPULATION:
Sixty females with a current diagnosis of Bipolar Affective Disorder or Schizoaffective
disorder - Manic Phase, according to the operationalised criteria of the Diagnostic and
Statistical Manual, 4th edition (DSM-IV) of the American Psychiatric Association.
STUDY MEDICATION:
Tamoxifen. One third of patients (twenty) will be randomized to receive adjunctive Tamoxifen
at 40 mg/day for 28 days. The Tamoxifen will be administered within a plain capsule to
maintain "blinding" of treatment arm.
Progesterone. One third of patients (twenty) will be randomized to receive adjunctive oral
Provera (progesterone) at 20 mg/day. The Progesterone will be administered within a plain
capsule identical to that used with Tamoxifen.
Placebo. The remaining one third of patients will be randomized to receive adjunctive
placebo (inert substance). The placebo substance will be administered within a plain capsule
identical to that used with Tamoxifen and Progesterone.
STUDY EVALUATIONS:
Data will be collected over a 28-day period for each patient. Visits will be performed at
baseline, and then at weekly intervals. A total of five visits will be completed for each
patient. The following evaluations will be performed:
- Psychiatric evaluation to determine diagnosis. (Baseline visit only)
- General clinical evaluation including medical history, current conditions and a
non-invasive physical examination, body weight, vital signs. (Baseline visit only)
- Medication history (baseline and evaluation visits).
- Demographics (baseline visits only).
- Completion of clinical rating scales; CARS-M, PANSS, MADRS, AIMS, Barnes Akathisia
scale (BA), and Simpson-Angus scale (SA) (baseline and evaluation visits). A Menstrual
Cycle Interview and a cognitive assessment (RBANS) will be performed at baseline and
endpoint (day 28) visit.
- Laboratory tests including; Serum levels of mood stabilizer, luteinizing hormone (LH),
follicle-stimulating hormone (FSH), Estrogen, Progesterone, Prolactin,
dehydroepiandrosterone (DHEA), Testosterone and protein kinase C(PKC) (baseline and
evaluation visits).
- Inclusion/exclusion checklist (baseline visit only).
- Informed consent (baseline visit only).
Status | Completed |
Enrollment | 51 |
Est. completion date | December 2007 |
Est. primary completion date | December 2007 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 50 Years |
Eligibility |
Inclusion Criteria: - Female patients who have a current diagnosis of Bipolar Affective Disorder (Manic phase) or Schizoaffective Disorder (Bipolar type in manic phase). - Female patients who are able to give informed consent. Exclusion Criteria: - Female patients who are pregnant or lactating. - Female patients with postpartum psychosis or related disorder. - Female patients with known abnormalities in the hypothalamo-pituitary gonadal-axis, thyroid dysfunction, central nervous system tumors. - Female patients taking estrogen preparations such as the oral contraceptive pill. - Female patients currently taking interacting drugs including warfarin, aminoglutethimide, diuretics, methyldopa, theophylline, fluoxetine, calcium channel blockers and non-steroidal anti-inflammatory drugs. - Female patients whose psychotic illness is directly due to illicit drugs or who have a history of substance abuse or dependence during the last 6 months. - Females with any significant unstable medical illness such as cardiovascular disease, renal disease, Addisons disease, thromboembolic disorders, epilepsy, diabetes etc. |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Australia | Bayside Health - The Alfred Hospital | Melbourne | Victoria |
Lead Sponsor | Collaborator |
---|---|
The Alfred | National Health and Medical Research Council, Australia, Stanley Medical Research Institute |
Australia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Scores on CARS-M Scale at trial completion | Baseline and weeks 1, 2, 3 and 4 | ||
Secondary | Scores on PANSS at trial completion (4 weeks) | Baseline and weeks 1, 2, 3 and 4 | ||
Secondary | Scores on MADRS at trial completion (4 weeks) | Baseline and weeks 1, 2, 3 and 4 | ||
Secondary | Scores on Adverse Symptom Checklist at trial completion (4 weeks) | Baseline and weeks 1, 2, 3 and 4 | ||
Secondary | Change in hormone levels over trial duration | Baseline and weeks 1, 2, 3 and 4 | ||
Secondary | Scores on RBANS at trial completion (4 weeks) | Baseline and week 4 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05111548 -
Brain Stimulation and Cognitive Training - Efficacy
|
N/A | |
Completed |
NCT02855762 -
Targeting the Microbiome to Improve Clinical Outcomes in Bipolar Disorder
|
N/A | |
Recruiting |
NCT05915013 -
Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response
|
Phase 1 | |
Recruiting |
NCT05206747 -
Ottawa Sunglasses at Night for Mania Study
|
N/A | |
Completed |
NCT02513654 -
Pharmacokinetics, Safety and Tolerability of Repeat Dosing Lamotrigine in Healthy Chinese Subjects
|
Phase 1 | |
Recruiting |
NCT06313918 -
Exercise Therapy in Mental Disorders-study
|
N/A | |
Completed |
NCT02304432 -
Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine
|
Early Phase 1 | |
Recruiting |
NCT06197048 -
Effect of Nutritional Counseling on Anthropometry and Biomarkers in Patients Diagnosed With Schizophrenia/Psychosis or Bipolar Affective Disorder
|
N/A | |
Completed |
NCT03497663 -
VIA Family - Family Based Early Intervention Versus Treatment as Usual
|
N/A | |
Completed |
NCT04284813 -
Families With Substance Use and Psychosis: A Pilot Study
|
N/A | |
Completed |
NCT02212041 -
Electronic Cigarettes in Smokers With Mental Illness
|
N/A | |
Recruiting |
NCT05030272 -
Comparing Two Behavioral Approaches to Quitting Smoking in Mental Health Settings
|
N/A | |
Recruiting |
NCT04298450 -
ED to EPI: Using SMS to Improve the Transition From the Emergency Department to Early Psychosis Intervention
|
N/A | |
Active, not recruiting |
NCT03641300 -
Efficacy of Convulsive Therapies for Bipolar Depression
|
N/A | |
Not yet recruiting |
NCT04432116 -
Time and Virtual Reality in Schizophrenia and Bipolar Disorder
|
N/A | |
Terminated |
NCT02893371 -
Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies
|
||
Completed |
NCT02970721 -
Use of Psychotropic Medications Among Pregnant Women With Bipolar Disorder
|
||
Terminated |
NCT02909504 -
Gao NARASD Lithium Study
|
Phase 4 | |
Recruiting |
NCT03088657 -
Design and Methods of the Mood Disorder Cohort Research Consortium (MDCRC) Study
|
||
Recruiting |
NCT02481245 -
BezafibrateTreatment for Bipolar Depression: A Proof of Concept Study
|
Phase 2 |